Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $215,040.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,000 shares of the business’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $17.92, for a total transaction of $215,040.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Joseph P. Lyssikatos also recently made the following trade(s):

• On Thursday, April 11th, Joseph P. Lyssikatos sold 30,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $751,200.00.
• On Monday, April 1st, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.60, for a total transaction of $223,200.00.
• On Thursday, February 29th, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.42, for a total transaction of $197,040.00.

Enliven Therapeutics Stock Up 7.9 %

NASDAQ ELVN opened at $22.65 on Friday. The company’s 50 day moving average is $17.42 and its 200-day moving average is $14.71. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $26.00. The firm has a market cap of $1.06 billion, a P/E ratio of -10.34 and a beta of 1.05.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. Equities analysts expect that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AJOVista LLC bought a new position in shares of Enliven Therapeutics in the 4th quarter worth $28,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Enliven Therapeutics in the 4th quarter valued at $66,000. Exchange Traded Concepts LLC boosted its stake in shares of Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after purchasing an additional 2,208 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Enliven Therapeutics during the 3rd quarter valued at $157,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Enliven Therapeutics by 9.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after buying an additional 1,029 shares during the period. Institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target on the stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.